American Association for Cancer Research
15417786mcr170135-sup-180386_2_supp_5012600_pkmzn1.pdf (4.78 MB)

Supplementary Data from Comprehensive Molecular Profiling of Olfactory Neuroblastoma Identifies Potentially Targetable FGFR3 Amplifications

Download (4.78 MB)
journal contribution
posted on 2023-04-03, 16:21 authored by Lorena Lazo de la Vega, Jonathan B. McHugh, Andi K. Cani, Komal Kunder, Frances M. Walocko, Chia-Jen Liu, Daniel H. Hovelson, Dan Robinson, Arul M. Chinnaiyan, Scott A. Tomlins, Paul W. Harms

Figure S1. (A) Overexpression of p53 in olfactory neuroblastoma tumor harboring an inactivating TP53 mutation. (B) Representative example of p53 expression in olfactory neuroblastoma tumor lacking TP53 mutation. Immunohistochemistry, 400x magnification. figure S2. (A) Nuclear localization of beta catenin in olfactory neuroblastoma tumor harboring an activating CTNNB1 mutation. (B) Representative example of membranous beta catenin expression in olfactory neuroblastoma tumor lacking CTNNB1 mutation. Immunohistochemistry, 400x magnification. Table S1: Immunohistochemistry protocols Table S2: Clinicopathologic features of olfactory neuroblastoma cohort Table S3: DNA sequencing statistics for profiled olfactory neuroblastoma samples Table S4: Prioritized somatic nonsynonymous mutations in olfactory neuroblastoma cases identified by next generation sequencing Table S5: FGFR3 copy number in olfactory neuroblastomas by next generation sequencing Table S6. Targeted multiplexed PCR based RNA sequencing statistics for ONB samples


A. Alfred Taubman Medical Research Institute

Department of Pathology, University of Michigan



Olfactory neuroblastomas (ONBs), also known as esthesioneuroblastomas, are malignant round-cell tumors that represent up to 5% of sinonasal malignancies. Despite their aggressive course, molecular studies of ONBs have been limited, and targeted therapies are lacking. To identify potential oncogenic drivers and targetable pathways in ONBs, we characterized 20 ONBs, including archived ONBs profiled by targeted, multiplexed PCR (mxPCR)–based DNA next-generation sequencing (NGS) of the coding sequence of over 400 cancer-relevant genes (n = 16), mxPCR-based RNA NGS of 108 target genes (n = 15), and 2 ONBs profiled by comprehensive hybrid-capture–based clinical grade NGS of >1,500 genes. Somatic mutations were infrequent in our cohort, with 7 prioritized nonsynonymous mutations in 5 of 18 (28%) ONBs, and no genes were recurrently mutated. We detected arm/chromosome-level copy-number alterations in all tumors, most frequently gains involving all or part of chromosome 20, chromosome 5, and chromosome 11. Recurrent focal amplifications, often but not exclusively in the context of arm-level gains, included CCND1 [n = 4/18 (22%) tumors] and the targetable receptor tyrosine kinase FGFR3 [n = 5/18 (28%) tumors]. Targeted RNA NGS confirmed high expression of FGFR3 in ONB (at levels equivalent to bladder cancer), with the highest expression observed in FGFR3-amplified ONB cases. Importantly, our findings suggest that FGFR3 may be a therapeutic target in a subset of these aggressive tumors.Implications: ONBs harbor recurrent chromosomal copy-number changes, including FGFR3 amplification associated with overexpression. Hence, FGFR3 may represent a novel therapeutic target in these tumors. Mol Cancer Res; 15(11); 1551–7. ©2017 AACR.

Usage metrics

    Molecular Cancer Research



    Ref. manager